Results 11 to 20 of about 56,774 (264)

Natalizumab for relapsing-remitting multiple sclerosis

Neurología (English Edition), 2011
Introduction: Natalizumab is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier and has been approved for the treatment of relapsing-remitting multiple sclerosis.
A. Horga, M. Tintoré
doaj   +3 more sources

Postural Control in Relapsing-Remitting Multiple Sclerosis [PDF]

International Archives of Otorhinolaryngology, 2022
Introduction Postural instability is considered one of the most disabling symptoms of relapsing-remitting multiple sclerosis (RRMS). Objective To evaluate postural control in patients with RRMS.
Flavia Salvaterra Cusin, Andreza Tomaz, Maurício Malavasi Ganança, Enedina Maria Oliveira, Alessandra Billi Falcão Gonçalves, Heloisa Helena Caovilla   +5 more
doaj   +3 more sources

Interferon in relapsing-remitting multiple sclerosis [PDF]

Cochrane Database of Systematic Reviews, 2001
Recombinant interferons have been shown to suppress both the clinical and magnetic resonance imaging (MRI) measures of disease activity in patients with relapsing remitting multiple sclerosis (RRMS).We performed a Cochrane review of all randomised, placebo-controlled trials of recombinant interferons in RRMS.Of 208 articles identified by a predefined ...
George PA Rice, Barbara Incorvaia, Luca M. Munari, George Ebers, Chris Polman, Roberto D'Amico, Elena Parmelli, Graziella Filippini   +7 more
openaire   +3 more sources

Natalizumab for relapsing remitting multiple sclerosis [PDF]

Cochrane Database of Systematic Reviews, 2009
Natalizumab (NTZ) (Tysabri(®)) is a monoclonal antibody that inhibits leukocyte migration across the blood-brain barrier, thus reducing inflammation in central nervous system, and has been approved worldwide for the treatment of relapsing-remitting multiple sclerosis (RRMS).To evaluate the efficacy, tolerability and safety of NTZ in the treatment of ...
Pucci, Eugenio, Giuliani, Giorgio, Solari, Alessandra, Simi, Silvana, Minozzi, Silvia, Di Pietrantonj, Carlo, Galea, Ian   +6 more
openaire   +4 more sources

Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis [PDF]

JAMA Neurology, 2023
ImportanceOcrelizumab, a humanized monoclonal antibody targeted against CD20+ B cells, reduces the frequency of relapses by 46% and disability worsening by 40% compared with interferon beta 1a in relapsing-remitting multiple sclerosis (MS). Rituximab, a chimeric monoclonal anti-CD20 agent, is often prescribed as an off-label alternative to ocrelizumab ...
Roos, Izanne, Hughes, Stella, McDonnell, Gavin, Malpas, Charles B., Sharmin, Sifat, Boz, Cavit, Alroughani, Raed, Ozakbas, Serkan, Buzzard, Katherine, Skibina, Olga, van der Walt, Anneke, Butzkueven, Helmut, Lechner-Scott, Jeannette, Kuhle, Jens, Terzi, Murat, Laureys, Guy, Van Hijfte, Liesbeth, John, Nevin, Grammond, Pierre, Grand'Maison, Francois, Soysal, Aysun, Jensen, Ana Voldsgaard, Rasmussen, Peter Vestergaard, Svendsen, Kristina Bacher, Barzinji, Ismael, Nielsen, Helle Hvilsted, Sejbæk, Tobias, Prakash, Sivagini, Stilund, Morten Leif Munding, Weglewski, Arkadiusz, Issa, Nadia Mubder, Kant, Matthias, Sellebjerg, Finn, Gray, Orla, Magyari, Melinda, Kalincik, Tomas, null, null, Cabrera-Gomez, Jose Antonio, Roullet, Etienne, Zwanikken, Cees, Den braber-Moerland, Leontien, Barnett, Michael, Hodgkinson, Suzanne, Garber, Justin, Slee, Mark, McCombe, Pamela, Taylor, Bruce, MacDonell, Richard, Massey, Jennifer, Van Pesch, Vincent, Decoo, Danny, Willekens, Barbara, Fragoso, Yara, Prevost, Julie, Prat, Alexandre, Girard, Marc, Grammond, Pierre, Larochelle, Catherine, Oh, Jiwon, Lalive, Patrice, Gobbi, Claudio, Horakova, Dana, Havrdova, Eva, Ampapa, Radek, Izquierdo, Guillermo, Eichau, Sara, Sanchez-Menoyo, Jose L., Ramo-Tello, Cristina, Blanco, Yolanda, Saiz, Albert, Besora, Sarah, Shaygannejad, Vahid, Cartechini, Elisabetta, Diamanti, Matteo, Amato, Maria Pia, Spitaleri, Daniele, Patti, Francesco, Chisari, Clara, D'Amico, Emanuele, Salvatore, Lo Fermo, Yamout, Bassem, Khoury, Samia J., Al-Asmi, Abdullah, Jose Sa, Maria, Al-Harbi, Talal, Karabudak, Rana, Turkoglu, Recai, Kilpatrick, Trevor, King, John, Nguyen, Ai-Lan, Dwyer, Chris, Monif, Mastura, Taylor, Lisa, Baker, Josephine   +93 more
openaire   +6 more sources

EХPERIENCE IN INTERFERON β-1A USE FOR TREATMENT OF MULTIPLE SCLEROSIS IN CHILDREN

Вопросы современной педиатрии, 2013
Aim: to evaluate the impact of subcutaneous interferon β-1a on matrix metalloproteinases 3, 8, 9 (MMP), cytokines (tumor necrosis factor α — TNF α, and transforming growth factor β1 — TGF β1) levels in serum of children with relapsing-remitting multiple ...
L. M. Kuzenkova, L. A. Pak, V.M. Studenikin, N. N. Shatilova, B. I. Bursagova, I. E. Smirnova   +5 more
doaj   +1 more source

Progressive multiple sclerosis: Prospects for disease therapy, repair, and restoration of function [PDF]

, 2017
Multiple sclerosis is a major cause of neurological disability, which accrues predominantly during progressive forms of the disease. Although development of multifocal inflammatory lesions is the underlying pathological process in relapsing-remitting ...
Cohen, JA, Fox, RJ, Ontaneda, D, Thompson, AJ   +3 more
core   +1 more source

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy

Italian Journal of Pediatrics, 2021
Background Natalizumab is a monoclonal antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis. According to the current clinical recommendations, its use during pregnancy should be carefully evaluated only in women ...
Elisabetta Godano, Fabio Barra, Alessandra Allodi, Antonella Ferraiolo, Alice Laroni, Giovanni Novi, Giovanni Luigi Mancardi, Claudio Gustavino, Cesare Arioni   +8 more
doaj   +1 more source

Interferon beta in multiple sclerosis: experience in a British specialist multiple sclerosis centre [PDF]

, 2003
Background: The efficacy of interferon beta (IFN beta) is well established in relapsing-remitting multiple sclerosis (MS). However, the use of this drug in clinical practice is complex, especially because it is only partially effective, its long term ...
Dubois, B.D., Giovannoni, G., Kapoor, R., Keenan, E., Miller, D.H., Porter, B.E,, Rudge, P., Thompson, A.J.   +7 more
core   +2 more sources

Intestinal Permeability in Relapsing-Remitting Multiple Sclerosis [PDF]

Neurotherapeutics, 2018
Changes of intestinal permeability (IP) have been extensively investigated in inflammatory bowel diseases (IBD) and celiac disease (CD), underpinned by a known unbalance between microbiota, IP and immune responses in the gut. Recently the influence of IP on brain function has greatly been appreciated. Previous works showed an increased IP that preceded
Buscarinu, M. C., Romano, S., Mechelli, R., Pizzolato Umeton, R., Ferraldeschi, M., Fornasiero, A., ReniÃ, R., Cerasoli, B., MORENA, EMANUELE, Romano, Carmela, Loizzo, N. D., Umeton, R., Salvetti, M., Ristori, G.   +13 more
openaire   +3 more sources